News
The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection ...
The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
The FDA approved Gilead’s landmark long-acting HIV treatment lenacapavir Wednesday afternoon. The drug will be marketed under ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results